Navigation Links
Gloucester Pharmaceuticals Reports Positive Interim Phase II Data,on Romidepsin for T-Cell Lymphomas at the 2007 American Society of,Clinical Oncology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, today announced that data for romidepsin as a treatment for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL. The data presented are part of an interim analysis of a phase II study of romidepsin sponsored by the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Gloucester.

Data from the NCI's ongoing clinical trial of romidepsin was presented in Abstract #8027 "Phase II Trial of Depsipeptide in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma" on Monday, June 4th.

The interim results reported on 70 patients with CTCL and 39 patients with PTCL. In the CTCL patient group 4 of 70 patients, or 6%, achieved a complete response, with the duration of response ranging from 8 to 63+ months. A partial response was observed in 18 of 70 patients, or 26%, with the duration of response ranging from 1 to 69+ months. The most common adverse events reported were nausea, vomiting, fatigue, transient granulocytopenia and thrombocytopenia, and anorexia.

Commenting on the data from the NCI's study, William McCulloch, M.B., FRCP, Executive Vice President and Chief Medical Officer at Gloucester said, "Clinical evidence for romidepsin's value in the treatment of T-cell lymphomas continues to build. Based on the data from this trial, as well as interim data from our own Gloucester-sponsored CTCL pivotal phase II study which is nearing completion, we remain enthusiastic about the clinical prospects for romidepsin."

In the PTCL patient group 3 of 39 patients, or 7%, achieved a complete response, with the duration of response ranging from 9 to 43+ months. A partial respons
'"/>




Page: 1 2 3

Related medicine technology :

1. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
2. Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib Combination in Non-Small Cell Lung Cancer Presented at American Association of Cancer Research Annual Meeting
3. Gloucester Pharmaceuticals Announces Multiple Presentations of Preclinical Romidepsin Data at American Association of Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:5/23/2013)... 2013 Amgen (NASDAQ: AMGN ) will ... Conference on Thursday, May 30, 2013, at the Westin Boston ... a.m. Eastern Daylight Time. Arvind Sood , ... the conference. Live audio of the presentation can be accessed ... under Investors. A replay of the webcast will also be ...
(Date:5/23/2013)... , May 23, 2013  A recently published ... Houston, Texas , demonstrates that 3D ... increasing cancer detection. The study, "Implementation ... Observational Study," was led by Stephen L. ... issue of the American Journal of Roentgenology ...
(Date:5/23/2013)... Anthem Blue Cross patients with HIV/AIDS may ... to obtain their medications by mail order under a ... LLC.  The lawsuit, filed in January ... mandatory mail order program announced late last year illegally ... "This settlement brings to a close a nerve-racking ...
Breaking Medicine Technology:First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
(Date:5/25/2013)... 25, 2013 This week idcloak Technologies releases ... Facebook in countries where the site is blocked. When ... faces none of the site compatibility problems associated with regular ... explains how a user may apply IP Port proxies to ... benefits of doing so are. , “When a user takes ...
(Date:5/25/2013)... Imagine running the air conditioner with the ... air and wasted energy! If the home has a folding ... clothes dryer, that may be just what is occurring in ... holes waste energy in the form of higher energy bills. ... in the home. , Drafts occur through the small cracks ...
(Date:5/25/2013)... May 25, 2013 It's not astonishing ... the year. The demands are endless, from family, friends ... buy, children who want more than their parents can ... after holiday season, comes graduations, birthdays, anniversaries and it ... some point gift ideas become tired and income can’t ...
(Date:5/25/2013)... Chandler, AZ (PRWEB) May 25, 2013 ... whitening service page in partnership with JD Media Surge, ... whitening methods are now available and, depending on the ... home. During a routine visit, the best method will ... whitening is performed during a visit. A special peroxide-based ...
(Date:5/25/2013)... Communities of Distinction TV announces May air ... media market in the United States with almost three million ... Texas and a major convention city. Ft. Worth is known ... is home to many major museums. Both cities offer a ... arts. Residents and locals will be able to watch the ...
Breaking Medicine News(10 mins):Health News:idcloak Launches Proxy Web Browser for Blocked Facebook Users 2Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 2Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 3Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 4Health News:TheBeautyPlace.com Debuts Their Brand New Beauty Kits 2Health News:Chandler Dentist Launches Teeth Whitening Service Page on Website in Partnership with JD Media Surge, LLC 2Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2
... class of drugs for treating,type 2 diabetes is under ... for Clinical Evaluative Sciences (ICES) finds that drugs such,as ... and death., Published in the December 12th issue ... drugs including rosiglitazone (Avandia) and,pioglitazone (Actos) in the first ...
... Early identification of adverse effects of drugs before they ... therapeutics, as unexpected effects account for a third of ... researchers at the University of California, San Diego (UCSD) ... identify potential side effects of pharmaceuticals, and have used ...
... -- In as many as one in five people ... blood around the body, some degree of backward leakage ... mitral regurgitation (MR). When sufficiently severe, MR causes buildup ... breathing (dyspnea, or "shortness of breath"), a serious condition ...
... predictor of heart disease, Britsh study says , TUESDAY, Dec. ... risk factor for heart disease, say British researchers who also ... of heart disease risk than waist measurement alone. , ... , included 24,508 men and women, ages 45 to 79, ...
... achievements place the field of microresonators at the ... issue of Optics Express, papers explore advanced silicon ... applications and the longest photon lifetime in a ... to Dr. Vasily Astratov from the University of ...
... is a familiar scenario experienced around the world: an outbreak ... one knows where it came from or how to stop ... people are affected, most often the very old and the ... fall ill, and people who were weak or unwell may ...
Cached Medicine News:Health News:More evidence suggests diabetes drug may be dangerous 2Health News:More evidence suggests diabetes drug may be dangerous 3Health News:New computational technique can predict drug side effects 2Health News:Exercise testing may help predict seriousness of mitral regurgitation 2Health News:Abdominal Fat Tied to High Risk for Coronary Trouble 2Health News:IBM reports milestone in silicon nanophotonics 2Health News:Scientists seek to assess the microbial risks in the water we drink 2Health News:Scientists seek to assess the microbial risks in the water we drink 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: